Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study

References

• HalperinDM, ShenC, DasariA, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534.28238592
   PubMed Web of Science ®Google Scholar
• AnthonyL, ErvinC, LapuertaP, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–2168. doi:10.1016/j.clinthera.2017.09.01329074312
   PubMed Web of Science ®Google Scholar
• ShenC, ChuY, HalperinDM, et al. Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. Oncologist. 2017;22(12):1451–1462. doi:10.1634/theoncologist.2017-014928642335
   PubMed Web of Science ®Google Scholar
• SinghS, GranbergD, WolinE, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43–53. doi:10.1200/JGO.2015.00298028717741
   PubMed Web of Science ®Google Scholar
• DasariA, ShenC, HalperinD, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi:10.1001/jamaoncol.2017.058928448665
   PubMed Web of Science ®Google Scholar
• Grozinsky-GlasbergS, GrossmanAB, GrossDJ. Carcinoid heart disease: from pathophysiology to treatment – “something in the way it moves”. Neuroendocrinol. 2015;101(4):263–273. doi:10.1159/000381930
   PubMed Web of Science ®Google Scholar
• DasariA, JoishVN, Perez-OlleR, et al. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol. 2019;25(47):6857–6865. doi:10.3748/wjg.v25.i47.685731885426
   PubMed Web of Science ®Google Scholar
• BroderMS, ChangE, RomanusD, CherepanovD, NearyMP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol. 2016;22(6):2118–2125. doi:10.3748/wjg.v22.i6.211826877616
   PubMed Web of Science ®Google Scholar
• DasariA, JoishVN, Perez-OlleR, et al. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res. 2020;20:507–511.31448649
   PubMed Web of Science ®Google Scholar
• KulkeMH, HörschD, CaplinME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23. doi:10.1200/JCO.2016.69.278027918724
   PubMed Web of Science ®Google Scholar
• PavelME, HörschD, CaplinM, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–1519. doi:10.1210/jc.2014-224725636046
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology – v2. 2020: neuroendocrine and adrenal tumors. Available from:http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed 728, 2020.
   Google Scholar
• DardenC, JoishVN, PriceMA, et al. Patient-reported activity impairment, work productivity loss, and carcinoid syndrome outcomes: interim analyses of the XERMELO patient registry. Presented at the North American Neuroendocrine Tumor Society virtual symposium; 102–3, 2020. Paper no. 113.
   Google Scholar
• PriceMA, JoishVN, SchwartzS, et al. XERMELO patient registry: improvements in clinical outcomes, patient satisfaction, and weight with telotristat ethyl in the real-world. In: Annual Symposium of the North American Neuroendocrine Tumor Society; Boston, Massachusetts; 103–5, 2019. Paper no. ID77.
   Google Scholar
• StrosbergJ, JoishVN, GiacaloneS, et al. TELEPRO: patient-reported carcinoid syndrome symptom improvement following initiation of telotristat ethyl in the real world. Oncologist. 2019;24(11):1446–1452. doi:10.1634/theoncologist.2018-092131189618
   PubMed Web of Science ®Google Scholar
• BensonAB, StrosbergJ, JoishVN, et al. Clinical benefits of telotristat ethyl in patients with neuroendocrine tumors and low bowel movement frequency: an observational patient-reported outcomes study. Pancreas. 2020;49(3):408–412. doi:10.1097/MPA.000000000000149632132510
   PubMed Web of Science ®Google Scholar
• HudgensS, GableJ, KulkeM, et al. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. Presented at the annual meeting of the Gastrointestinal Cancers Symposium; January 19–21; 2017; San Francisco, CA.
   Google Scholar
• Food and Drug Administration. Center for drug evaluation and research. Summary Review. Application Number 208794Orig1s000. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000SumR.pdf. Accessed 1019, 2018.
   Google Scholar
• SiddiquiEJ, ShabbirMA, MikhailidisDP, MumtazFH, ThompsonCS. The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int. 2006;97:634–639. doi:10.1111/j.1464-410X.2006.06056.x16469039
   PubMed Web of Science ®Google Scholar
• IshizukaJ, BeauchampRD, TownsendCM, GreeleyGH, ThompsonJC. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol. 1992;150(1):1–7. doi:10.1002/jcp.10415001021309821
   PubMed Web of Science ®Google Scholar
• DrozdovI, KiddM, GustafssonBI, et al. Auto-regulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer. 2009;115(21):4934–4945. doi:10.1002/cncr.2453319634160
   PubMed Web of Science ®Google Scholar
• JoishVN, ShahS, TierceJC, et al. Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis. Future Oncol. 2019;15(12):1397–1406. doi:10.2217/fon-2018-096030734573
   PubMed Web of Science ®Google Scholar
• Lexicon Pharmaceuticals, Inc. Xermelo® (telotristat ethyl) prescribing information; 2017. Available from: https://www.xermelo.com/Media/Default/pdfs/Product_Info_telotristat_ethyl.pdf. Accessed 36, 2020.
   Google Scholar